Open AccessPerturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Author(s) -
Li Jiang,
Bennett Keiryn,
Stukalov Alexey,
Fang Bin,
Zhang Guolin,
Yoshida Takeshi,
Okamoto Isamu,
Kim JaeYoung,
Song Lanxi,
Bai Yun,
Qian Xiaoning,
Rawal Bhupendra,
Schell Michael,
Grebien Florian,
Winter Georg,
Rix Uwe,
Eschrich Steven,
Colinge Jacques,
Koomen John,
SupertiFurga Giulio,
Haura Eric B
Publication year - 2013
Publication title -
molecular systems biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.523
H-Index - 148
ISSN - 1744-4292
DOI - 10.1038/msb.2013.61
Subject(s) - interactome , biology , erlotinib , gefitinib , epidermal growth factor receptor , cancer research , phosphoproteomics , lung cancer , computational biology , cancer , bioinformatics , phosphorylation , microbiology and biotechnology , genetics , protein phosphorylation , protein kinase a , gene , oncology , medicine
We hypothesized that elucidating the interactome of epidermal growth factor receptor (EGFR) forms that are mutated in lung cancer, via global analysis of protein–protein interactions, phosphorylation, and systematically perturbing the ensuing network nodes, should offer a new, more systems‐level perspective of the molecular etiology. Here, we describe an EGFR interactome of 263 proteins and offer a 14‐protein core network critical to the viability of multiple EGFR‐mutated lung cancer cells. Cells with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) had differential dependence of the core network proteins based on the underlying molecular mechanisms of resistance. Of the 14 proteins, 9 are shown to be specifically associated with survival of EGFR‐mutated lung cancer cell lines. This included EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A. With the use of a drug network associated with the core network proteins, we identified two compounds, midostaurin and lestaurtinib, that could overcome drug resistance through direct EGFR inhibition when combined with erlotinib. Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance.